Kelly R Peck1, Taylor A Ochalek2, Gary J Badger3, Stacey C Sigmon2. 1. Vermont Center on Behavior and Health, University of Vermont, 1 S. Prospect Street, Burlington, VT 05401, United States. Electronic address: Kelly.Peck@uvm.edu. 2. Vermont Center on Behavior and Health, University of Vermont, 1 S. Prospect Street, Burlington, VT 05401, United States. 3. University of Vermont, Department of Biostatistics, 27 Hills Building, 105 Carrigan Drive, Burlington, VT 05405, United States.
Abstract
OBJECTIVE: Although opioid maintenance is a first-line approach for treating opioid use disorder (OUD), suboptimal treatment outcomes have been reported among emerging adults (EAs; 18-25 years of age). In this secondary analysis, we compared treatment outcomes between EAs and older adults (OAs; ≥ 26 years of age) receiving low-barrier, technology-assisted Interim Buprenorphine Treatment (IBT) during waitlist delays to comprehensive opioid maintenance treatment. METHOD: Participants were 35 individuals with OUD who received IBT consisting of 12-weeks of buprenorphine maintenance with bi-monthly clinic visits and technology-assisted monitoring. At monthly follow-up assessments, participants completed staff-observed urinalysis, the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II), and Addiction Severity Index (ASI). RESULTS: At study intake, EAs (n = 10) reported greater past-year intravenous drug use and greater employment, legal, and psychiatric severity (p's < .05) compared to OAs (n = 25). Despite these initial differences, there were no significant differences in the percentages of urine specimens testing negative for illicit opioids between EA and OA participants at Study Week 4 (90 % vs. 88 %, p = .99), Week 8 (80 % vs. 76 %, p = .99) or Week 12 (60 % vs. 68 %, p = .71). Relative to their older peers, EAs also demonstrated significantly greater improvements on the BAI, BDI-II, and ASI Employment and Legal subscales (p's < .05). CONCLUSIONS: Despite presenting with greater past-year intravenous drug use and psychosocial severity relative to OAs, EAs responded favorably to the IBT intervention.
OBJECTIVE: Although opioid maintenance is a first-line approach for treating opioid use disorder (OUD), suboptimal treatment outcomes have been reported among emerging adults (EAs; 18-25 years of age). In this secondary analysis, we compared treatment outcomes between EAs and older adults (OAs; ≥ 26 years of age) receiving low-barrier, technology-assisted Interim Buprenorphine Treatment (IBT) during waitlist delays to comprehensive opioid maintenance treatment. METHOD:Participants were 35 individuals with OUD who received IBT consisting of 12-weeks of buprenorphine maintenance with bi-monthly clinic visits and technology-assisted monitoring. At monthly follow-up assessments, participants completed staff-observed urinalysis, the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II), and Addiction Severity Index (ASI). RESULTS: At study intake, EAs (n = 10) reported greater past-year intravenous drug use and greater employment, legal, and psychiatric severity (p's < .05) compared to OAs (n = 25). Despite these initial differences, there were no significant differences in the percentages of urine specimens testing negative for illicit opioids between EA and OA participants at Study Week 4 (90 % vs. 88 %, p = .99), Week 8 (80 % vs. 76 %, p = .99) or Week 12 (60 % vs. 68 %, p = .71). Relative to their older peers, EAs also demonstrated significantly greater improvements on the BAI, BDI-II, and ASI Employment and Legal subscales (p's < .05). CONCLUSIONS: Despite presenting with greater past-year intravenous drug use and psychosocial severity relative to OAs, EAs responded favorably to the IBT intervention.
Authors: Scott E Hadland; J Frank Wharam; Mark A Schuster; Fang Zhang; Jeffrey H Samet; Marc R Larochelle Journal: JAMA Pediatr Date: 2017-08-01 Impact factor: 16.193
Authors: Steven L Proctor; Amy L Copeland; Albert M Kopak; Norman G Hoffmann; Philip L Herschman; Nadiya Polukhina Journal: Psychol Addict Behav Date: 2015-06-22
Authors: George E Woody; Sabrina A Poole; Geetha Subramaniam; Karen Dugosh; Michael Bogenschutz; Patrick Abbott; Ashwin Patkar; Mark Publicker; Karen McCain; Jennifer Sharpe Potter; Robert Forman; Victoria Vetter; Laura McNicholas; Jack Blaine; Kevin G Lynch; Paul Fudala Journal: JAMA Date: 2008-11-05 Impact factor: 56.272
Authors: Christopher M Jones; Joseph Logan; R Matthew Gladden; Michele K Bohm Journal: MMWR Morb Mortal Wkly Rep Date: 2015-07-10 Impact factor: 17.586
Authors: Celestina Barbosa-Leiker; Aimee N C Campbell; Martina Pavlicova; Jennifer Scodes; A Kathleen Burlew; Mary Hatch-Maillette; Sarah E Mennenga; Shannon G Mitchell; Patricia Novo; Edward V Nunes; John Rotrosen; Shelly F Greenfield Journal: Am J Addict Date: 2020-05-21
Authors: Darren Chai; Tea Rosic; Balpreet Panesar; Nitika Sanger; Emma A van Reekum; David C Marsh; Andrew Worster; Lehana Thabane; Zainab Samaan Journal: JAMA Netw Open Date: 2021-08-02